RNA Therapeutics Insights to Accelerate Drug Candidate Evaluation

Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do once they get there? This webinar examines how integrating complementary analytical tools can answer both, providing a more straightforward path to safer, more effective oligonucleotide therapeutics (ONT).

Sensitive antibody detection panels enable universal detection of key chemical modifications across a wide range of oligonucleotide modalities, including ASOs and siRNA. These reagents are sensitive and versatile tools for localization, quantification and trafficking; they bind independently of nucleic acid composition, structure or strandedness, and are optimized for immunocytochemistry (ICC), immunofluorescence microscopy (IF), ELISA, immunohistochemistry (IHC) and other immunoassays. This level of understanding is essential for confirming delivery to target tissues and uncovering potential off-target exposure early in development.

Building on these insights, next-generation sequencing–based approaches map small RNA–target interactions directly across the transcriptome. By directly mapping small RNA–target interactions across the transcriptome, these assays reveal where siRNAs bind, how they influence RNA processing and their downstream impact on gene expression, offering a powerful, data-driven view of specificity and efficacy.

Together, these complementary technologies provide a comprehensive view of RNA therapeutic performance by showing where candidates localize and how they act. Attendees will learn how combining these approaches can de-risk candidate selection, refine delivery strategies and accelerate the journey from discovery to clinic.

Register for this webinar to learn how RNA therapeutics development benefits from integrated detection and functional characterization strategies.

Speakers

Todd Giardiello, Business Development Manager, Rockland Immunochemicals, Inc.

Todd Giardiello serves as the Business Development Manager for Rockland’s Complex Therapy Solutions line of business. His expertise focuses on supporting partners in detecting and quantifying oligonucleotide localization, biodistribution and potency using ModDetect™ Panels. With a Bachelor of Science in Microbiology from Kutztown University and more than 18 years at Rockland, Todd brings a unique combination of hands-on scientific experience and strategic insight to advancing RNA therapeutic research.

Message Presenter

Diana Cox, PhD, Senior Scientist, Eclipsebio

Dr. Diana Cox has an extensive background in alternative splicing and post-transcriptional regulation, with research focused on how miRNAs and RNA-binding proteins influence disease mechanisms. Since joining Eclipsebio in 2020, she has been instrumental in developing the miR-eCLIP+ assay, a next-generation sequencing method that enables precise mapping of miRNA–target interactions to advance RNA biology and therapeutic discovery.

Message Presenter